替吉奥联合奥沙利铂化疗在老年胃癌中的应用价值

目的探讨替吉奥联合奥沙利铂在老年胃癌治疗中的应用价值。方法选择2010年6月至2012年8月梅河口市中心医院收治的老年胃癌患者作为研究对象,按照随机数字表法分为观察组（替吉奥联合奥沙利铂化疗）和对照组（卡培他滨联合奥沙利铂化疗）,观察两组患者肿瘤缓解情况、内分泌指标及不良反应发生情况。结果观察组肿瘤缓解情况显著优于对照组（H=7.193,P〈0.05）;血清血管内皮生长因子A、血管内皮生长因子C水平显著低于对照组[（92.1±13.6）ng/L vs（134.2±19.8）ng/L]（t=6.237,P〈0.05）,[（34.4±8.4）ng/L vs（58.6±7.4）ng/L]（t=6.842,P〈0.05）,可溶性血管内皮生长因子受体1水平却显著高于对照组[（682.5±90.4）ng/L vs（411.3±73.6）ng/L]（t=5.384,P〈0.05）;恶心呕吐、头痛头晕、心功能损害、肾功能损害、肝功能损害等不良反应例数均显著低于对照组。结论替吉奥联合奥沙利铂化疗能够显著改善胃癌患者的化疗效果及肿瘤内分泌情况,减少不良反应。

The Application Value of Tegafur,Gimeracil Oteracil Potassium Combined with Oxaliplatin in Treating Elderly Patients with Gastric Carcinoma

Objective To study the application value of tegafur,gimeracil oteracil potassium combined with oxaliplatin in treating elderly patients with gastric carcinoma. Methods The elderly patients with gastric carcinoma from Meihekou City Central Hospital during Jun. 2010 and Aug. 2012 were enrolled and divided into observation group（ tizio combined with oxaliplatin） and control group（ capecitabine combined with oxaliplatin） by random number table method. The tumor remission,endocrine indexes and adverse reactions were observed. Results The tumor remission condition of observation group was better than control group（ H = 7. 193,P 0. 05）. VEGFA, VEGFC levels were significantly lower than control group [（ 92. 1 ± 13. 6） ng/L vs（ 134. 2 ± 19. 8） ng/L]（ t =6.237,P 0.05）,[（ 34.4 ± 8. 4） ng/L vs（ 58. 6 ± 7. 4） ng/L]（ t = 6. 842,P 0. 05）,sVEGFR-1（ t = 5. 384,P 0. 05） level was significantly higher than control group[（ 682. 5 ± 90. 4） ng/L vs（ 411. 3 ± 73. 6） ng/L]（ t =5.384,P 0.05）,the cases of nausea and vomiting,headache and dizziness,cardiac functional damage,renal functional damage,and liver functional damage were significantly lower than the control group. Conclusion Tegafur,gimeracil oteracil potassium combined with oxaliplatin can significantly improve the effect of chemotherapy and tumor endocrine,and reduce the adverse reactions.